Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. more
Time Frame | LIPO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.21% | 0.31% | -1.26% |
1-Month Return | 12.81% | 0.6% | -4.16% |
3-Month Return | -6.84% | -9.44% | -0.46% |
6-Month Return | -16.34% | -5.15% | 3.58% |
1-Year Return | -63.03% | 0.33% | 22.47% |
3-Year Return | -91.92% | 4.53% | 25.13% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 694.75K | 961.68K | 259.35K | 184.16K | 449.62K | [{"date":"2019-12-31","value":72.24,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":26.97,"profit":true},{"date":"2022-12-31","value":19.15,"profit":true},{"date":"2023-12-31","value":46.75,"profit":true}] |
Cost of Revenue | 682.89K | 975.96K | 1.46M | 2.55M | 3.04M | [{"date":"2019-12-31","value":22.47,"profit":true},{"date":"2020-12-31","value":32.12,"profit":true},{"date":"2021-12-31","value":47.94,"profit":true},{"date":"2022-12-31","value":83.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 11.86K | (14.28K) | (1.20M) | (2.36M) | (2.59M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-120.41,"profit":false},{"date":"2021-12-31","value":-10099.05,"profit":false},{"date":"2022-12-31","value":-19933.55,"profit":false},{"date":"2023-12-31","value":-21837.05,"profit":false}] |
Gross Margin | 1.71% | (1.48%) | (461.71%) | (1283.43%) | (575.87%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-86.99,"profit":false},{"date":"2021-12-31","value":-27053.69,"profit":false},{"date":"2022-12-31","value":-75201.43,"profit":false},{"date":"2023-12-31","value":-33742.6,"profit":false}] |
Operating Expenses | 748.54K | 1.02M | 2.18M | 2.77M | 2.16M | [{"date":"2019-12-31","value":26.99,"profit":true},{"date":"2020-12-31","value":36.72,"profit":true},{"date":"2021-12-31","value":78.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":77.75,"profit":true}] |
Operating Income | (53.79K) | (56.86K) | (1.92M) | (2.59M) | (4.75M) | [{"date":"2019-12-31","value":-5379000,"profit":false},{"date":"2020-12-31","value":-5686200,"profit":false},{"date":"2021-12-31","value":-191582800,"profit":false},{"date":"2022-12-31","value":-258971300,"profit":false},{"date":"2023-12-31","value":-474595300,"profit":false}] |
Total Non-Operating Income/Expense | - | (9.59K) | 43.63K | (15.91K) | 208.60K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-4.6,"profit":false},{"date":"2021-12-31","value":20.91,"profit":true},{"date":"2022-12-31","value":-7.63,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (61.85K) | (61.66K) | (1.87M) | (2.60M) | (4.62M) | [{"date":"2019-12-31","value":-6184800,"profit":false},{"date":"2020-12-31","value":-6165600,"profit":false},{"date":"2021-12-31","value":-186547300,"profit":false},{"date":"2022-12-31","value":-259769200,"profit":false},{"date":"2023-12-31","value":-461896500,"profit":false}] |
Income Taxes | (53.79K) | 4.79K | 6.73K | (1.63K) | 5.00 | [{"date":"2019-12-31","value":-799.27,"profit":false},{"date":"2020-12-31","value":71.23,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-24.26,"profit":false},{"date":"2023-12-31","value":0.07,"profit":true}] |
Income After Taxes | - | (66.45K) | (1.87M) | (2.60M) | (4.62M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-6645000,"profit":false},{"date":"2021-12-31","value":-187220300,"profit":false},{"date":"2022-12-31","value":-259605900,"profit":false},{"date":"2023-12-31","value":-461897000,"profit":false}] |
Income From Continuous Operations | - | (61.66K) | (1.87M) | (2.60M) | (4.29M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-6165600,"profit":false},{"date":"2021-12-31","value":-186547300,"profit":false},{"date":"2022-12-31","value":-259769200,"profit":false},{"date":"2023-12-31","value":-429400600,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (61.85K) | (66.45K) | (1.87M) | (2.60M) | (4.62M) | [{"date":"2019-12-31","value":-6184800,"profit":false},{"date":"2020-12-31","value":-6645000,"profit":false},{"date":"2021-12-31","value":-187220300,"profit":false},{"date":"2022-12-31","value":-259605900,"profit":false},{"date":"2023-12-31","value":-461896500,"profit":false}] |
EPS (Diluted) | - | - | - | (0.42) | (5.02) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-42,"profit":false},{"date":"2023-12-31","value":-502.36,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
LIPO | |
---|---|
Cash Ratio | 1930.63 |
Current Ratio | 2966.35 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
LIPO | |
---|---|
ROA (LTM) | -93.77% |
ROE (LTM) | -171.56% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
LIPO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.32 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.00 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
LIPO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 7.26 |
P/B | 2.52 |
Price/FCF | NM |
EV/R | 4.96 |
EV/Ebitda | NM |
Lipella Pharmaceuticals Inc. Common Stock (LIPO) share price today is $3.046
Yes, Indians can buy shares of Lipella Pharmaceuticals Inc. Common Stock (LIPO) on Vested. To buy Lipella Pharmaceuticals Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LIPO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Lipella Pharmaceuticals Inc. Common Stock (LIPO) via the Vested app. You can start investing in Lipella Pharmaceuticals Inc. Common Stock (LIPO) with a minimum investment of $1.
You can invest in shares of Lipella Pharmaceuticals Inc. Common Stock (LIPO) via Vested in three simple steps:
The 52-week high price of Lipella Pharmaceuticals Inc. Common Stock (LIPO) is $10.4. The 52-week low price of Lipella Pharmaceuticals Inc. Common Stock (LIPO) is $2.21.
The price-to-earnings (P/E) ratio of Lipella Pharmaceuticals Inc. Common Stock (LIPO) is
The price-to-book (P/B) ratio of Lipella Pharmaceuticals Inc. Common Stock (LIPO) is 2.52
The dividend yield of Lipella Pharmaceuticals Inc. Common Stock (LIPO) is 0.00%
The market capitalization of Lipella Pharmaceuticals Inc. Common Stock (LIPO) is $3.68M
The stock symbol (or ticker) of Lipella Pharmaceuticals Inc. Common Stock is LIPO